First profit achieved, but massive trial costs loom for 2027
- Madrigal generated $431.3 million in Q3 2026 net sales and recorded its first profitable quarter.
- The company updated its addressable market estimate to 360,000 F4c patients and will start a new Phase 3 trial in 2027.
- Gross-to-net discounts will widen in 2027 as Medicare Part D contracts take effect.
- European revenue remains negligible this year because of complex reimbursement negotiations.
- Three Phase 2 combination trials are scheduled to begin in 2027.
A U.S. blockbuster facing 2027 margin pressure
Madrigal continues to see massive demand for Rezdiffra in the U.S. market. In Q3 2026, the company crossed 55,850 active patients and reported $431.3 million in net sales. This volume growth pushed Rezdiffra past $1 billion in year-to-date sales and delivered the company's first quarter of profitability.
The company is aggressively expanding its target market. Madrigal increased its addressable patient estimate for the F4c cirrhosis market to 360,000 patients. To capture this group, the company will initiate a massive new 2,000-patient Phase 3 trial called MAESTRO-CSPH in early 2027.
The bear case now focuses on heavy costs and pricing headwinds expected next year. Initiating the MAESTRO-CSPH trial and three Phase 2 combination studies will require a massive spike in research and development spending. Management warned that profitability may dip in and out as these costs hit the income statement.
Adding to the pressure, gross-to-net discounts will step up to the high end of the 30 percent range in 2027 as Medicare Part D contracts activate. Investors must weigh the flawless commercial execution against a tightening margin profile and delayed European expansion.
Selling through liver specialists
Madrigal makes money entirely from Rezdiffra. The company sells the drug in the U.S. through a limited specialty pharmacy network. The main prescribers are hepatologists, gastroenterologists, and an expanding group of endocrinologists.
Because this is a first-in-disease launch, Madrigal bears the full cost of market education. It must teach doctors how to find the right patients, help offices process prescriptions, and secure payer coverage. This creates a strong early lead but requires significant upfront investment.
The moat relies on patent protection. Madrigal holds U.S. patents extending exclusivity to 2045, covering the commercial weight-based dosing regimen. New patents also protect the drug in the F2 and F3 disease stages, which complicates potential future generic entry.
While all current revenue comes from the U.S., Madrigal is trying to open the European market. However, strict price controls and Most Favored Nation pricing rules make those negotiations very difficult.
One drug, many follow-ons
Rezdiffra
The only commercial product and total revenue base today. It is approved for noncirrhotic NASH with moderate to advanced liver fibrosis.
F4 cirrhosis expansion
Supported by the MAESTRO-NASH OUTCOMES trial reading out in late 2027 and the new MAESTRO-CSPH trial starting in early 2027.
MGL-2086
An oral GLP-1 program meant to support combination treatments. A Phase 2 combination trial is expected to start in 2027.
Ervogastat
A DGAT2 inhibitor brought in to build combination therapy options, with Phase 2 trials planned for 2027.
MGL-0795
An siRNA therapeutic recently in-licensed. This adds another mechanism to the pipeline, also slated for 2027 Phase 2 trials.
U.S. sales and European delays
For Q3 2026, Madrigal reported $431.3 million of product revenue. The internal segment view treats all material current revenue as U.S. Rezdiffra sales. Europe is modeled as a zero-revenue segment this year due to reimbursement challenges.
What could break the thesis
Margin pressure from Medicare
High impact · High oddsGross-to-net discounts are expected to increase in 2027 to the high end of the 30 percent range as Medicare Part D contracts activate. This will pressure unit economics just as the company accelerates research spending.
Return to cash burn
High impact · Medium oddsMadrigal achieved profitability in Q3 2026, but the massive new MAESTRO-CSPH trial and three Phase 2 combination trials require heavy spending next year. This research burden could push the company back into meaningful losses.
European reimbursement failures
High impact · High oddsManagement expects negligible European revenue this year because of tough pricing negotiations. If Madrigal cannot secure favorable reimbursement abroad, the total addressable market shrinks.
Future drug competition
High impact · Medium oddsNASH is a massive market, and other companies are developing treatments, including GLP-1 drugs. While Madrigal has a lead, better data from a competitor could erode its dominance.
In one breath
What does Madrigal Pharmaceuticals do?
Madrigal sells Rezdiffra, a drug for certain NASH patients with moderate to advanced liver scarring. It also builds a pipeline of follow-on treatments in the same disease area.
Why is Rezdiffra important?
Rezdiffra was the first approved drug for its target NASH population. That gives Madrigal a massive early lead with doctors, payers, and specialty pharmacies.
Is Madrigal profitable?
The company reported its first profitable quarter in Q3 2026. However, heavy research spending on new clinical trials starting in 2027 could push the company back into temporary losses.
What is the next big catalyst for MDGL?
The next year centers on the initiation of the large MAESTRO-CSPH trial in early 2027, monitoring Medicare pricing impacts, and the expected late 2027 readout for the F4 cirrhosis outcomes trial.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 8, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Madrigal Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

